miRCURY LNA™ microRNA Antisense Controls

Negative control inhibitors for quality assessment of your in vitro microRNA inhibition experiment

Niels M. Frandsen, Ph.D., Product Manager Back

Similar in length of sequence and LNA™ design to our miRCURY LNA™ microRNA Inhibitor and Power Inhibitor
No homology to any known microRNA or mRNA sequences in mouse, rat or human

Coverage

We currently offer four pre-designed microRNA Antisense Controls - two miRCURY LNA™ microRNA Antisense Controls and two miRCURY LNA™ microRNA Power Antisense Controls with the phosphorothioate backbone to match the miRCURY LNA™ microRNA Power Inhibitors.

For each of the inhibitor product categories we have the following two microRNA Antisense Control offerings:

Antisense Control A (resemble the former Scramble-miR control): No hits of >70% homology to any sequence in any organism in the NCBI and miRBase databases.

Anitisense Control B (resemble the former Sense miR-159 control): No hits of >70% homology to any human, mouse or rat sequence in the NCBI and miRBase databases. Not recommended for use in plants.

All microRNA Antisense Controls are available as ready-to-label or as pre-labeled 3’ and 5’ fluorescein (6-FAM) oligonucleotides similar to the miRCURY LNA™ microRNA Inhibitors and Power Inhibitors. The Antisense Controls are HPLC-purified and desalted and delivered in tubes containing 5 nmol dried-down oligonucleotide ready for transfection or electroporation using standard techniques.

Note

For information on how to design your own microRNA Antisense Control, please go to Custom miRCURY LNA™ microRNA Inhibitors.

To view the Antisense Control sequences, please click on your probe of interest in the table below.

View experimental data on the miRCURY LNA™ microRNA Inhibitors and Power Inhibitors

"LNA microRNA antisense inhibitors are efficient and specific with long lasting effects"

Dr. Annick Harel-Bellan (AHB) is Directeur de Recherche at the Institut Andre Lwoff in Paris. She heads a group working on epigenetics and cancer (Laboratoire Epigenetique et Cancer). Dr. Anna Polesskaya (AP) is a senior scientist and longstanding member of this group

Read full story...

"We chose to use miRCURY LNA™ knockdown probes as we had previous experience with using LNA probes for in situ hybridization with great success".

Amanda Dixon-McIver is finishing her Ph.D. under the supervision of Dr. Silvana Debernardi, in the Medical Oncology Laboratory headed by Prof. Bryan Young in the Institute of Cancer, Barts Hospital, in London, UK.

Read full story...